TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 3-D Motion Analysis- gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-D Motion Analysis- active straight leg raise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum Klotho levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo controlled similarity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Serotonin Transporter Availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of ICP variation or increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum tolerated dose of XmAb®2513
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose of XmAb®2513
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of patient's aggravation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of patient's aggravation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord blood immune responses against hepatitis C virus and influenza virus vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-reported adherence on antiretroviral therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of general Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mortality rate in children aged 2-11 months
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of severe adverse drug reactions following IPTi
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of ear-EEG wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epileptic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Circulating FFA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FFA turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of vessels patent without requiring intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Identify antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TETRAS Subset Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADL Scale Subset Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Urine Output (ml/kg/hr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Serum Creatinine (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Levels of Serum Albumin (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Onset Latency From Sleep Diary
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wake After Sleep Onset From Sleep Diary
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: major postoperative adverse events (MPAE)
Endpoint domain: Adverse events/effects
Primary endpoint: clinical changes after surgical treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and toxicity of the TAC regimen with bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline expression of HIF1α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in muscle mass measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of CMS bundle completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Embolic events
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Social Communication Deficits
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of Participants with Suicidality
Endpoint domain: Adverse events/effects
Primary endpoint: Change in medication related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: World Health Organization (WHO) Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional Assessment of Cancer Therapy, Brain Cancer (FACT-Br)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Edmonton Symptom Assessment Scale (ESAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-c30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Isokinetic maximum leg strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: success of regional anesthesia procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bayley Scales of Infant Development (BSID) Cognitive Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in M2-TAM Infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Radial Artery Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Heart rate measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electrocardiogram (ECG) assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in amount of gingival display
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Social Network Interaction System Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Satisfaction with Interpersonal Relationships Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mother-Infant Bonding Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Evidence of toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total consumption of alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total daily OFF time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of tourniquet pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in walking mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Antibody response to HPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Scores of One shot feasibility questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Composite performance measures for ACS care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemorrhage event rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline Melanin Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: visual evoked potentials (VEP) waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Electroretinography (ERG) waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mRNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Widespread Pain Index (WPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Severity (SS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visualization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Blood Cortisol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Average Blood Testosterone Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: timely recovery of ANC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to positive (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Early bactericidal activity (EBA) of WX-081
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of progression to mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjective Well-Being (Affect)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Well-Being (Life Satisfaction)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy in eradicating HIV-1 integrated DNA from PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy in eradicating HIV-1 integrated DNA from CD34+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Blood Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Prevalence of cardiac sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Effectiveness based on Clinical Rating Scale for Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Therapeutic response monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Hematologic Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of new cases of IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hematological, biochemical and cardiovascular parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of Delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Life change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: GO overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violence behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NAS cut off for identifying care level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR detection in urinary cell free DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatment days completed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in active range of motion of shoulder, elbow, and wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fitzpatrick Elastosis Score (FES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall Global Aesthetic Improvement (GAI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Chronic Respiratory Disease Questionnaire (CRQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Occurrence of Acute Kidney Injury (AKI) during therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of optical enhancement endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of optical enhancement endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive predictive value of optical enhancement endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative predictive value of optical enhancement endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Efficacy of recruitment maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of recruitment maneuvers
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Estrogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in Progesterone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pre to Post Ratio of Image Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Need for stopping the meeting for coagulation of the circuit of dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in the venous pressure of the circuit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall mental health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of Avelumab in combination with decitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Hair Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Changes/Updates in Medication List
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in HAM-D17 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of language functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Antirecombinant Thrombin Product Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Helicobacter pylori distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-∞) of Digoxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HADS Anxiety Subscale Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in management practice pattern
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of treated veins with recanalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of treated limbs with neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Prediction of treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma-concentration time curve (AUC) of GSK2118436
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of GSK2118436
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time until C. trachomatis testing of partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck flexor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence Rate of Pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: microalbuminuria improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Feasibility of system use
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Subjects With Dose-limiting Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Lumbar disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: slope of the torque-angle curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guideline-Concordant Antibiotic Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinically Relevant Findings in Physical Examination, Vital Signs and Clinical Laboratory Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Relevant Findings in Electrocardiogram (ECG) Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Micturition Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Resection rates (R0 or R1) for hepatic metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Assessment Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Progression-free at 9 Months
Endpoint domain: Mortality/survival
Primary endpoint: Neointimal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eating Disorder Inventory-2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eating attitudes test (EAT)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brown Assessment of Beliefs Scale (BABS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: RECIST v 1.1 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Point prevalence abstinence rate at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Reserve of Donor Kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reductions of viral titers in the oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma concentrations of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HIT-6 scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Morningness-eveningness scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: GAD-7 scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: insulin demand per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of loss of clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of loss of biological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculatory Flow Index (MFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to Occipital Nerve Block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in objective child physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in fat%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in lean tissue%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of eyes achieving target IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum plasma concentration (Cmax) of ACT-132577
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curves during a dosing interval [AUC(0-t)] of ACT-132577
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curves from time 0 to inf [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Interleukin-6 (IL-6) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to PONV Guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vital sign parameters (temperature, pulse, respiratory rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported peripheral sensory neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: User Performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: System Use Evaluation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use